07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-31 (miR-31); neuronal nitric oxide synthase 1 (NOS1; nNOS)

Cardiovascular disease INDICATION: Fibrillation Cell culture and goat studies suggest inhibiting miR-31 could help treat atrial fibrillation (AF). miR-31 levels were higher in atrial myocytes from AF patients and in the left ventricle of a...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of immune complex-mediated kidney disease A mouse model of immune complex-mediated kidney disease could help identify new therapeutic strategies to treat the condition....
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Infertility Neurokinin 3 receptor (TACR3; NK3R); gonadotropin-releasing hormone (GnRH) In vitro and goat studies identified peptidomimetic NK3R agonists that could help treat infertility. Senktide,...
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; obesity Ghrelin O-Acyltransferase (GOAT) In vitro and mouse studies suggest that inhibiting GOAT could help treat endocrine disorders including obesity and diabetes. In...
08:00 , Dec 9, 2010 |  BC Innovations  |  Targets & Mechanisms

Going for GOAT

A team led by researchers from The Johns Hopkins University has developed the first biologically active inhibitors of ghrelin O -acyltransferase-a recently discovered enzyme that activates the appetite-stimulating hormone ghrelin. The inhibitors are licensed to...
08:00 , Feb 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Ghrelin O-acyltransferase (GOAT) Mouse genome studies identified GOAT as a potential obesity target. GOAT was found to be the...
08:00 , Feb 28, 2008 |  BC Innovations  |  Targets & Mechanisms

Getting Ghrelin's GOAT

When the discovery of ghrelin was reported in 1999, the appetite-stimulating hormone was hotly pursued by biotech and pharma companies, with agonists aimed at treating various wasting syndromes and antagonists geared toward treating obesity. 1...
07:00 , Jun 28, 2004 |  BioCentury  |  Politics, Policy & Law

What's in a model?

Drug development relies heavily on animal models to validate targets, to anticipate the effect of a drug on a target of interest, and to assess potential side effects. Yet despite the fact that creating good...
07:00 , Apr 19, 2004 |  BioCentury  |  Strategy

Making the 'make' decision

Drug discovery and development is like the portion of an iceberg that is above water: visible and dramatic. Manufacturing is like the portion that is under water: out of sight and often out of mind....
07:00 , May 29, 2001 |  BC Week In Review  |  Company News

Elan, Genzyme Transgenics deal

In a second antibody deal between the companies, GZTC will use its transgenic goats to produce an undisclosed ELN antibody. GZTC also is developing ELN’s Antegren natalizumab humanized monoclonal antibody against integrin alpha(4) in goat’s...